BioCentury | Jan 5, 2018
Financial News

Boehringer increases investment fund, expands focus

...and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH and vaccine developer Okairos AG...
...NYSE:MRK) said in September 2017 it would acquire Rigontec, while GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) bought Okairos...
...Boehringer Ingelheim GmbH, Ingelheim, Germany Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) GlaxoSmithKline plc Merck & Co. Inc. Okairos AG Rigontec...
BioCentury | Jan 3, 2018
Financial News

Boehringer Ingelheim enlarges investment fund

...and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH and vaccine developer Okairos AG...
...NYSE:MRK) said in September 2017 it would acquire Rigontec, while GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) bought Okairos...
BioCentury | Dec 21, 2017
Emerging Company Profile

Neoantigens for all

...is that the platform is based on vectors developed by the company’s founders while at Okairos AG...
...over 4,000 healthy volunteers, and induced “a very strong CD8 + T cell response,” he said.Okairos...
BioCentury | Nov 10, 2017
Finance

Vaccine dream team

...tranches are undisclosed. Five members of Nouscom’s executive team hail from infectious disease vaccine company Okairos AG...
...million ($323 million). LSP and Versant were also investors in Okairos. Nouscom has rights to Okairos’...
...said. Lloyd-Harris noted that the vectors have been tested in more than 4,000 patients through Okairos’...
BioCentury | Aug 31, 2017
Finance

Fund fine-tuning

...told BioCentury. Among BioMedPartners’ best exits, two garnered multiples of 7x or better: vaccine play Okairos AG...
...or B rounds and it plans to continue seeding corporate spinouts as it did with Okairos...
BioCentury | Dec 31, 2016
Finance

Versant’s capstone

...muscles after heart attacks. Geographic reach Bolzon added that CRISPR, along with Swiss vaccine developer Okairos AG...
...great assets and great technology out of Europe and operationalize in the U.S.,” Bolzon said. Okairos...
...with Versant co-leading its €16 million ($20.7 million) B round in 2010. GlaxoSmithKline plc acquired Okairos...
BioCentury | Aug 1, 2016
Strategy

Bug battle plan

...GSK's vaccine technologies, including the chimpanzee-derived adenovirus (ChAd) vector technology it obtained when it acquired Okairos AG...
BioCentury | May 18, 2016
Financial News

Cancer vaccine play Nouscom raises EUR 12M

...the senior management team at vaccine company Okairos AG . LSP and Versant both invested in Okairos...
BioCentury | Aug 24, 2015
Finance

Versant bites at the apple

...$24.39, giving Flexion a market cap of $524 million. Versant's third crack in Europe - Okairos AG...
...old Merck organization that had built up their adenoviral vector program in the vaccine space." Okairos'...
...Ricerche di Biologia Molecolare (IRBM), a Rome subsidiary of Merck & Co. Inc. Versant co-led Okairos'...
BioCentury | Apr 27, 2015
Politics, Policy & Law

Speed trials

...result of its acquisition of Swiss biotech Okairos AG . The vaccine was being developed by Okairos...
...When GSK embarked on the project in August it had never manufactured the vaccine, and Okairos...
Items per page:
1 - 10 of 36
BioCentury | Jan 5, 2018
Financial News

Boehringer increases investment fund, expands focus

...and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH and vaccine developer Okairos AG...
...NYSE:MRK) said in September 2017 it would acquire Rigontec, while GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) bought Okairos...
...Boehringer Ingelheim GmbH, Ingelheim, Germany Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) GlaxoSmithKline plc Merck & Co. Inc. Okairos AG Rigontec...
BioCentury | Jan 3, 2018
Financial News

Boehringer Ingelheim enlarges investment fund

...and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH and vaccine developer Okairos AG...
...NYSE:MRK) said in September 2017 it would acquire Rigontec, while GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) bought Okairos...
BioCentury | Dec 21, 2017
Emerging Company Profile

Neoantigens for all

...is that the platform is based on vectors developed by the company’s founders while at Okairos AG...
...over 4,000 healthy volunteers, and induced “a very strong CD8 + T cell response,” he said.Okairos...
BioCentury | Nov 10, 2017
Finance

Vaccine dream team

...tranches are undisclosed. Five members of Nouscom’s executive team hail from infectious disease vaccine company Okairos AG...
...million ($323 million). LSP and Versant were also investors in Okairos. Nouscom has rights to Okairos’...
...said. Lloyd-Harris noted that the vectors have been tested in more than 4,000 patients through Okairos’...
BioCentury | Aug 31, 2017
Finance

Fund fine-tuning

...told BioCentury. Among BioMedPartners’ best exits, two garnered multiples of 7x or better: vaccine play Okairos AG...
...or B rounds and it plans to continue seeding corporate spinouts as it did with Okairos...
BioCentury | Dec 31, 2016
Finance

Versant’s capstone

...muscles after heart attacks. Geographic reach Bolzon added that CRISPR, along with Swiss vaccine developer Okairos AG...
...great assets and great technology out of Europe and operationalize in the U.S.,” Bolzon said. Okairos...
...with Versant co-leading its €16 million ($20.7 million) B round in 2010. GlaxoSmithKline plc acquired Okairos...
BioCentury | Aug 1, 2016
Strategy

Bug battle plan

...GSK's vaccine technologies, including the chimpanzee-derived adenovirus (ChAd) vector technology it obtained when it acquired Okairos AG...
BioCentury | May 18, 2016
Financial News

Cancer vaccine play Nouscom raises EUR 12M

...the senior management team at vaccine company Okairos AG . LSP and Versant both invested in Okairos...
BioCentury | Aug 24, 2015
Finance

Versant bites at the apple

...$24.39, giving Flexion a market cap of $524 million. Versant's third crack in Europe - Okairos AG...
...old Merck organization that had built up their adenoviral vector program in the vaccine space." Okairos'...
...Ricerche di Biologia Molecolare (IRBM), a Rome subsidiary of Merck & Co. Inc. Versant co-led Okairos'...
BioCentury | Apr 27, 2015
Politics, Policy & Law

Speed trials

...result of its acquisition of Swiss biotech Okairos AG . The vaccine was being developed by Okairos...
...When GSK embarked on the project in August it had never manufactured the vaccine, and Okairos...
Items per page:
1 - 10 of 36